Marshall Wace LLP Buys 63,139 Shares of Silk Road Medical, Inc (NASDAQ:SILK)

Marshall Wace LLP increased its stake in Silk Road Medical, Inc (NASDAQ:SILK) by 16.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440,254 shares of the company’s stock after buying an additional 63,139 shares during the period. Marshall Wace LLP’s holdings in Silk Road Medical were worth $11,904,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Capital World Investors grew its holdings in shares of Silk Road Medical by 4.9% during the 1st quarter. Capital World Investors now owns 3,111,730 shares of the company’s stock worth $57,007,000 after acquiring an additional 145,000 shares during the period. Cetera Advisors LLC purchased a new stake in Silk Road Medical in the first quarter worth $710,000. First Eagle Investment Management LLC bought a new position in Silk Road Medical in the first quarter worth $1,605,000. Birchview Capital LP lifted its position in Silk Road Medical by 282.8% during the fourth quarter. Birchview Capital LP now owns 158,094 shares of the company’s stock valued at $1,940,000 after buying an additional 116,800 shares during the period. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Silk Road Medical during the 1st quarter valued at $12,313,000.

Silk Road Medical Stock Down 0.0 %

NASDAQ:SILK opened at $27.49 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 6.69 and a current ratio of 7.63. The firm has a market cap of $1.12 billion, a P/E ratio of -20.07 and a beta of 1.53. Silk Road Medical, Inc has a fifty-two week low of $6.08 and a fifty-two week high of $27.51. The firm has a 50-day simple moving average of $27.18 and a two-hundred day simple moving average of $23.41.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The firm had revenue of $51.20 million for the quarter, compared to the consensus estimate of $49.74 million. Silk Road Medical had a negative net margin of 29.53% and a negative return on equity of 37.30%. Silk Road Medical’s revenue was up 13.0% on a year-over-year basis. During the same period last year, the business earned ($0.35) EPS. Analysts predict that Silk Road Medical, Inc will post -1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SILK. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research note on Thursday, July 11th. Lake Street Capital restated a “hold” rating and issued a $27.50 price objective (down previously from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $27.50 target price (up from $23.00) on shares of Silk Road Medical in a report on Wednesday, July 17th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.29.

Insider Transactions at Silk Road Medical

In related news, EVP Kevin M. Klemz sold 2,268 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $27.10, for a total transaction of $61,462.80. Following the sale, the executive vice president now directly owns 162,926 shares of the company’s stock, valued at $4,415,294.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.90% of the company’s stock.

Silk Road Medical Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.